Skip to main content
IMCC
NASDAQ Life Sciences

IM Cannabis Q3 Revenue Falls 68% to C$1.65M; Going-Concern Warning Reiterated

Arie Shkolnikov · Analysis by Wiseek AI
More coverage: Pharmaceutical Stocks · Healthcare
Sentiment info
Negative
Importance info
8
Price
$0.58
Mkt Cap
$936.106K
52W Low
$0.5
52W High
$62.4
52W Position info
16% above low
Off High info
99% below high
Rel. Volume info
0.1× avg
Market data snapshot near publication time

IMCC sits 16% above its 52-week low of $0.5 on light trading volume (0.1× avg).

Summary

IM Cannabis reported Q3 2026 continuing-operations revenue of C$1.65M, down 68% year over year, a small gross loss, and a C$13.93M nine-month net loss, while repeating substantial doubt about its ability to continue as a going concern.


Key Events · Earnings and Guidance · IMCC

  • Q3 Revenue Collapses 68%

    Revenue from continuing operations was C$1.65M versus C$5.08M in Q3 2025; nine-month revenue fell 43% to C$8.96M from C$15.77M.

  • Quarter Swings to Gross Loss

    Q3 gross loss of C$0.04M versus C$1.58M gross profit a year earlier; nine-month gross profit fell 73% to C$1.33M.

  • Going-Concern Warning Reiterated

    Management cites a C$2.99M shareholders' deficit, C$5.5M working capital deficit and C$2.4M cash, stating substantial doubt about the ability to continue as a going concern.

  • Losses Balloon on Financing Costs

    Nine-month net loss was C$13.93M versus C$3.88M in 2025, driven by lower gross profit and C$4.64M of net finance expense.


Analysis · IMCC · Life Sciences

The Israeli medical cannabis business is shrinking faster than costs can be cut: revenue from continuing operations collapsed to C$1.65M in Q3 from C$5.08M a year earlier, and the quarter swung to a small gross loss. Against just C$2.4M of cash, the company now carries a C$2.99M shareholders' deficit and a C$5.5M working capital hole, and management states substantial doubt about its ability to continue as a going concern. What keeps the balance sheet afloat is serial convertible-note issuance (a US$1.2M note closed November 4, 2026) and the C$2.7M accounting gain on selling the German operations to a company controlled by the CEO. For a company this small, the going-concern language plus the revenue collapse is the story; the equity is a financing vehicle, not an operating business.

How filings like this one have moved

In the 30 days to Nov 12, 2026, 47.3% of the 1873 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was -0.17%. These are measured outcomes after filings of this importance, not a forecast for this one.

Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset

At the time of this filing, IMCC was trading at $0.58 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $936.1K. The 52-week trading range was $0.50 to $62.40. This filing was assessed with negative market sentiment and an importance score of 8 out of 10.

View Main SEC Filing

Price Chart

Share this article

Copied!

IMCC - Latest Insights

IMCC
Nov 10, 2026, 4:16 PM EST
Filing Type: F-3
Importance Score:
8
Price at Filing: $0.590
Real-time Price: $0.590 info
Change: $0 (0%) info
Market Cap: $936.106K info
IMCC
Nov 04, 2026, 4:13 PM EST
Filing Type: 6-K
Importance Score:
8
Price at Filing: $0.716
Real-time Price: $0.590 info
Change: -$0.126 (-18%) info
Market Cap: $936.106K info
IMCC
Nov 04, 2026, 4:01 PM EST
Source: PR Newswire
Importance Score:
7
Price at Filing: $0.7168
Real-time Price: $0.590 info
Change: -$0.1268 (-18%) info
Market Cap: $936.106K info
IMCC
Oct 08, 2026, 4:06 PM EDT
Filing Type: F-3
Importance Score:
8
Price at Filing: $1.72
Real-time Price: $0.590 info
Change: -$1.13 (-66%) info
Market Cap: $936.106K info
IMCC
Oct 02, 2026, 5:25 PM EDT
Filing Type: 6-K
Importance Score:
7
Price at Filing: $2.00
Real-time Price: $0.590 info
Change: -$1.41 (-70%) info
Market Cap: $936.106K info